THE AURORA KINASE A INHIBITOR ALISERTIB IS SYNERGISTIC WITH IRINOTECAN AND CARBOPLATIN AGAINST GLIOBLASTOMA CELLS

被引：0
|
作者：
Burton, Eric [1 ]
Zumbar, Cory [2 ]
King, Paul [3 ]
Sak, Muge [2 ]
Usubalieva, Aisulu [3 ]
Li, Xiaohui [3 ]
Mifsud, Caroline [3 ]
McElroy, Joseph [3 ]
Lehman, Norman [2 ]
机构：
[1] Univ Louisville, Sch Med, Dept Neurol, Div Neurooncol, Louisville, KY 40292 USA
[2] Univ Louisville, Louisville, KY 40292 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EXTH-75
引用
收藏
页码：101 / 101
页数：1
相关论文
共 50 条
  • [1] The AURKA Inhibitor Alisertib Is Synergistic With Irinotecan And Carboplatin Against Glioblastoma Cells
    Zumbar, Cory
    King, Paul
    Sak, Muge
    Usubalieva, Aisulu
    Li, Xiaohui
    Mifsud, Caroline
    McElroy, Joseph
    Burton, Eric
    Lehman, Norman
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2018, 77 (06): : 491 - 492
  • [2] Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells
    Sak, Muge
    Zumbar, Cory T.
    King, Paul D.
    Li, Xiaohui
    Mifsud, Caroline S.
    Usubalieva, Aisulu
    Anderson, Charles D.
    Chesnick, Hailey M.
    McElroy, Joseph P.
    Chakravarti, Arnab
    Burton, Eric C.
    Lehman, Norman L.
    JOURNAL OF NEURO-ONCOLOGY, 2019, 143 (02) : 231 - 240
  • [3] Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells
    Müge Sak
    Cory T. Zumbar
    Paul D. King
    Xiaohui Li
    Caroline S. Mifsud
    Aisulu Usubalieva
    Charles D. Anderson
    Hailey M. Chesnick
    Joseph P. McElroy
    Arnab Chakravarti
    Eric C. Burton
    Norman L. Lehman
    Journal of Neuro-Oncology, 2019, 143 : 231 - 240
  • [4] A role of aurora A tyrosine kinase inhibitor, Alisertib, in the resistance of cancer cells to Daunorubicin
    Yati, S.
    Novotna, E.
    Wsol, V.
    TOXICOLOGY LETTERS, 2024, 399 : S380 - S381
  • [5] Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
    Pitts, Todd M.
    Bradshaw-Pierce, Erica L.
    Bagby, Stacey M.
    Hyatt, Stephanie L.
    Selby, Heather M.
    Spreafico, Anna
    Tentler, John J.
    McPhillips, Kelly
    Klauck, Peter J.
    Capasso, Anna
    Diamond, Jennifer R.
    Davis, S. Lindsey
    Tan, Aik Choon
    Arcaroli, John J.
    Purkey, Alicia
    Messersmith, Wells A.
    Ecsedy, Jeffery A.
    Eckhardt, S. Gail
    ONCOTARGET, 2016, 7 (31) : 50290 - 50301
  • [6] An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor
    Durlacher, Cameron T.
    Li, Zhi-Ling
    Chen, Xiao-Wu
    He, Zhi-Xu
    Zhou, Shu-Feng
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2016, 43 (06) : 585 - 601
  • [7] Aurora-A inhibitor alisertib potentiates VEGFR inhibitors in glioblastoma cell lines
    Smith, Kendall
    Mifsud, Caroline
    Zumbar, Cory
    Lehman, Norman
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [8] Molecular mechanism underlying acquired resistance to Aurora A kinase inhibitor, Alisertib, in melanoma
    Vilgelm, Anna E.
    Liu, Yan
    Levy, Shawn
    Richmond, Ann
    CANCER RESEARCH, 2012, 72
  • [9] ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
    Michaelis M.
    Selt F.
    Rothweiler F.
    Wiese M.
    Cinatl J.
    Jr.
    BMC Research Notes, 8 (1)
  • [10] The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells
    Zumbar, Cory T.
    Usubalieva, Aisulu
    King, Paul D.
    Li, Xiaohui
    Mifsud, Caroline S.
    Dalton, Hailey M.
    Sak, Muge
    Urio, Sara
    Bryant, William M.
    McElroy, Joseph P.
    Farmer, George
    Lehman, Norman L.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (03) : 481 - 492
12345